Biogen Exceeds Second Quarter Expectations as Rare Disease Portfolio Offsets MS Decline

Biogen surpassed Wall Street performance targets for the second quarter as newer treatments and rare-disease therapies compensated for shrinking revenue in its multiple sclerosis division. Yahoo Finance reports that while earnings beat analyst projections, the pharmaceutical gian